Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

Rapid Communications in Mass Spectrometry

Volumn 18, Issue 23, 2004, Pages 2839-2848

  Beumer, Jan Hendrik ^a   Rosing, Hilde ^a   Hillebrand, Michel J X ^a   Nan Offeringa, Lianda G A H ^a   Foley, Karen ^b   Yule, S Murray ^b   Heck, Albert J R ^c   Schellens, Jan H M ^c,d   Beijnen, Jos H ^a,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b EISAI CO LTD   (Japan)

^c UTRECHT UNIVERSITY   (Netherlands)

^d ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMOLECULES; DRUG PRODUCTS; ELECTROSPRAY IONIZATION; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NEGATIVE IONS; PATIENT MONITORING; PHASE SEPARATION; PLASMA (HUMAN); ROOM TEMPERATURE;

ANALYTES; ANTICANCER DRUG; BIOLOGICAL MATRIXES; CONCENTRATION RANGES; ELECTROSPRAY IONIZATION TANDEM MASS SPECTROMETRY; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN FECES; HUMAN PLASMAS; HUMAN URINE; QUANTITATIVE DETERMINATIONS;

METABOLITES;

'M1'; 1,4 BENZENEDISULFONAMIDE; ACETIC ACID ETHYL ESTER; ANTINEOPLASTIC AGENT; DEUTERIUM; DRUG METABOLITE; INDISULAM; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BLOOD ANALYSIS; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG MONITORING; DRUG STRUCTURE; DRUG URINE LEVEL; ELECTROSPRAY; EQUIPMENT; FECES ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LINEARITY; LIQUID LIQUID EXTRACTION; MOLECULAR STABILITY; PARAMETER; PRODUCT RECOVERY; QUANTITATIVE ANALYSIS; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; URINALYSIS; VALIDATION PROCESS;

EID: 9644279613     PISSN: 09514198     EISSN: None     Source Type: Journal    
DOI: 10.1002/rcm.1699     Document Type: Article

References (7)

1. Raymond E, Bokkel Huinink WW, Taieb J, Beijnen JH, Faivre S, Wanders J, Ravic M, Fumoleau P, Armand JP, Schellens JH. J. Clin. Oncol. 2002; 20: 3508.
2. Van Kesteren C, Beijnen JH, Schellens JHM. Anticancer Drugs 2002; 13: 989.
3. Fukuoka K, Usuda J, Iwamoto Y, Fukumoto H, Nakamura T, Yoneda T, Narita N, Saijo N, Nishio K. Invest New Drugs 2001; 19: 219.
4. Ozawa Y, Sugi NH, Nagasu T, Owa T, Watanabe T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K. Eur. J. Cancer 2001; 37: 2275.
5. Punt CJ, Fumoleau P, van de Walle B, Faber MN, Ravic M, Campone M. Ann. Oncol. 2001; 12: 1289.
6. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine Guidance for Industry-Bioanalytical Method Validation, 2001. Available: http://www.fda.gov/cder/guidance/index.htm.
7. Rosing H, Man WY, Doyle E, Bult A, Beijnen JH. J. Liquid Chromatogr. Related Technol. 2000; 23: 329.